Etom

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etom

Quick Facts

Property Description
Active ingredient Etoricoxib
Form Film-coated tablet
Pharmacological class Selective Cyclooxygenase-2 (COX-2) Inhibitor (Coxib)
Common use Relief of pain and inflammation
Origin Synthetic compound

What Type of Medicine is Etom (Etoricoxib)?

Etom is a brand-name, synthetic medicinal product containing the active substance etoricoxib, which is a Non-Steroidal Anti-Inflammatory Drug (NSAID). The drug is categorized specifically as a selective Cyclooxygenase-2 (COX-2) inhibitor, placing it within the pharmacological subclass known as a coxib. This product is typically available as a prescription-only medicine, manufactured as a single active ingredient formulation. This class of medication is utilized for conditions requiring consistent pain management and anti-inflammatory action.

The General Purpose and Form of Etom

The overall purpose of Etom is to provide systemic relief by reducing the body's inflammatory response. The medicine functions by initiating the selective inhibition of prostanoid biosynthesis, translating to the general therapeutic aim of decreasing the production of prostaglandins—the primary chemical messengers associated with pain and swelling. Etoricoxib is a selective COX-2 inhibitor with anti-inflammatory and analgesic effects. The core function of this drug is to manage discomfort by reducing the chemical triggers of inflammation. Etom is administered as a single active ingredient product, formulated as a film-coated tablet for oral administration.

Etom's Unique Action Compared to Traditional NSAIDs

The differentiation in Etom's action lies in its targeted mechanism, which exhibits selectivity for COX-2 over the COX-1 enzyme. While traditional NSAIDs typically inhibit both enzymes, this high selectivity is designed to focus on COX-2 activity. This targeted intervention supports a once-daily dosing regimen and is intended to address inflammation and pain while minimizing interference with baseline functions associated with COX-1. This property is a primary characteristic of its use in patient management.

Regulatory References

  1. EMA Etoricoxib Referral Overview

What side effects are possible with Etom?

Possible Side Effects and Safety Information

The official safety profile of Etom (Etoricoxib) documents possible adverse reactions classified by frequency and body system. The classification utilizes regulatory tiers ranging from Very Common to Rare based on clinical incidence data, providing a systematic view of potential effects.

Adverse reactions are grouped by the affected System-Organ Class (SOC), with common effects noted in the Gastrointestinal (e.g., abdominal pain, nausea, heartburn), Vascular (e.g., hypertension), and Nervous Systems (e.g., headache, dizziness). Elevated ALT and AST (liver enzymes) are also classified as common findings.

Serious Adverse Reactions

The regulatory profile explicitly highlights the risks of serious gastrointestinal events (bleeding, ulceration, or perforation) and serious cardiovascular events, including myocardial infarction and stroke. The risk of these cardiovascular events is formally documented to increase with both dose and duration of exposure.

Rare but serious adverse reactions also include anaphylactic/anaphylactoid reactions and severe skin conditions such as Stevens-Johnson syndrome.

Population and Constraint Notes

The use of Etom carries specific constraints defined in the regulatory labeling. The medicine is contra-indicated for individuals under 16 years of age. Furthermore, specific contraindications exist for patients with pre-existing conditions, including established congestive heart failure (NYHA Class II-IV), established ischaemic heart disease, and severe hepatic dysfunction (Child-Pugh score ge 10). Safety considerations also apply to older adults, who are recognized as being at increased risk for gastrointestinal adverse events.

Overdose and Emergency Response

Etom Overdose and When to Seek Help — Official Regulatory Information

Overdose manifestations for Etom (Etoricoxib) are defined by an exaggeration of the drug’s known toxicities, primarily affecting major physiological systems. Documented presentations include severe symptoms linked to the Gastrointestinal (GI), Cardiovascular (CV), Renal, and Hepatic systems. These can involve serious GI complications (ulcers, bleedings), hypertension, confusion, and signs of fluid retention.

Required Emergency Actions

Over-ingestion is officially classified as potentially leading to severe or life-threatening outcomes, including major thrombotic events (myocardial infarction or stroke) and organ failure. Due to these established risks, regulatory labeling mandates patients to seek medical attention immediately and report to the nearest hospital emergency department if an excessive dose is suspected. Elderly patients and those with pre-existing organ impairment are officially noted to be at higher risk for severe complications.

Management and Monitoring

No specific antidote is known for Etoricoxib overdose. Management is therefore strictly defined as symptomatic and supportive treatment. Procedural steps such as activated charcoal or gastric lavage may be considered for recent, massive ingestions. Hospital monitoring is required for severe symptoms, with specific attention directed toward evaluating renal and liver function.

Therapeutic Uses of Etom

What Etom Treats: Main Uses and Benefits

Etom is relevant in contexts marked by increased discomfort or tension, and is used in areas where short-term symptom management is appropriate.

Medications of this class are applicable within clinical settings that involve acute or disruptive symptom patterns.

This medication is relevant for easing challenging symptoms in conditions characterized by periods of heightened symptoms, such as aches and muscular pain, localized swelling, and fever. It may assist with providing supportive relief when symptoms interfere with routine activities.

“This medication is applied in scenarios where additional management of discomfort is required, and contributes to easing the overall symptom load.”

It is applied in addressing symptom clusters related to inflammatory or irritative states, which may assist with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Use in Acute Symptom Episodes Etom is commonly used across conditions presenting with acute episodes where the symptoms may intensify temporarily, and short-term symptomatic support is appropriate.

Regulatory References

  1. NIH MedlinePlus overview of OTC pain relievers

Eligibility and Restrictions for Use

The eligibility for using Etom (Etoricoxib) is strictly defined by official regulatory labeling, which outlines specific age, physiological, and comorbidity-based restrictions.

Eligibility Scope

Category Official Regulatory Status and Specific Population/Condition
Populations for whom use is allowed (as stated in label): Adults and adolescents 16 years of age and older, provided no absolute contraindications exist.
Populations for whom use is not recommended (if applicable): Women who are planning or attempting to conceive.
Populations for whom use is contraindicated: Individuals with known hypersensitivity to Etoricoxib, aspirin, or any other NSAIDs.
Age-related eligibility rules: Children and adolescents under 16 years of age are contraindicated from use.

Condition-Specific Eligibility Rules

Condition/Status Official Regulatory Status (Exclusion)
Established Ischaemic Heart, Peripheral Arterial, or Cerebrovascular Disease Contraindicated
Congestive Heart Failure (NYHA Class II-IV) Contraindicated
Uncontrolled Hypertension (blood pressure persistently elevated >140/90 mmHg) Contraindicated
Active Peptic Ulceration or Active Gastrointestinal Bleeding Contraindicated
Severe Hepatic Dysfunction (Child-Pugh score ge 10) Contraindicated
Severe Renal Impairment (estimated creatinine clearance <30 mL/min) Contraindicated
Pregnancy and Lactation Contraindicated

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with established cardiovascular disease, uncontrolled high blood pressure, and active gastrointestinal pathology.
  • Use is contraindicated in patients with severe hepatic dysfunction or severe renal impairment.
  • The medicine must not be used by individuals under mathbf16 years of age, or by women who are pregnant or breastfeeding.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use Etom primarily through a list of absolute contraindications that strictly exclude populations with specific pre-existing cardiovascular, gastrointestinal, or organ-function vulnerabilities. Use is thus confined to eligible adults over 16 years old who do not possess any of the documented contraindications, with additional caution mandated for older adults and those with non-severe organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Etom (Etoricoxib) documents specific interaction patterns with other medicines, structured around pharmacokinetic and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or selective COX-2 inhibitors is restricted due to the potential for increased risk of adverse effects. Additionally, combining Etom with analgesic doses of Acetylsalicylic acid (Aspirin) is generally restricted due to the heightened risk of gastrointestinal complications.

Pharmacokinetic and Exposure-Altering Effects

Co-administration with the potent metabolic inducer Rifampicin results in a significant reduction of approximately 65% in Etoricoxib's plasma exposure (AUC). Conversely, Etom can increase the exposure of certain co-administered drugs: an increase in the steady-state AUC of Ethinyl Estradiol (a component of oral contraceptives) is documented, and a rise in plasma concentrations of both Lithium and Methotrexate has been reported.

Pharmacodynamic Effects and Monitoring

Etom may diminish the antihypertensive and natriuretic effects of diuretics and ACE inhibitors/Angiotensin II Antagonists. When combined with Warfarin and other oral anticoagulants, a documented increase in the International Normalized Ratio (INR) occurs, necessitating close monitoring upon initiation or change in Etom dosage. Food intake does not alter the overall exposure (AUC), but may delay the time to peak concentration (Tmax). No mandatory separation timing is specified in regulatory labeling.

Mechanism of Action

Mechanism of Action: Selective COX-2 Inhibition

Etom's active ingredient, etoricoxib, functions as a highly selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is the primary inducible isoform responsible for the biosynthesis of pro-inflammatory mediators at sites of tissue distress. Etoricoxib establishes a competitive interaction, suppressing the conversion of arachidonic acid into prostaglandins.

The resulting suppression of pro-inflammatory prostaglandin synthesis modifies the early molecular steps that govern systemic physiological outcomes. Specifically, this dampens the sensitization of nociceptors (pain-sensing nerves) and reduces local vascular permeability, which modulates heightened physiological responses.

A key characteristic is the functional sparing of the constitutive Cyclooxygenase-1 (COX-1) enzyme. This high selectivity preserves prostaglandin synthesis necessary for homeostatic functions, including the maintenance of gastric mucosal integrity and platelet aggregation, allowing the physiological activity of these pathways to continue unimpeded. The mechanism also extends to the central nervous system, where its action modifies prostaglandin-mediated signals influencing thermoregulation.

Dosage and Administration Information

How to Use Etom (Etoricoxib)

Etom (etoricoxib) is administered orally as a film-coated tablet across all approved indications, utilizing a once-daily (every 24 hours) dosing schedule. The medication may be taken with or without food; however, administration without food may result in a faster onset of its effect, which may be relevant when rapid symptomatic relief is required.


Official Dosing and Duration Principles

The dosage is strictly dependent upon the condition being addressed, and the general principle is to use the lowest effective daily dose for the shortest duration possible. Doses exceeding the officially recommended maximums should not be used.

Clinical Condition Standard Daily Dose (Maximum) Maximum Treatment Duration
Osteoarthritis (OA) 30 mg or 60 mg Chronic (Re-evaluate periodically)
Rheumatoid Arthritis (RA) / Ankylosing Spondylitis (AS) 60 mg or 90 mg Chronic (Re-evaluate periodically)
Acute Gouty Arthritis 120 mg 8 days
Postoperative Dental Pain 90 mg 3 days

Population-Specific Adjustments

Older adults typically do not require dosage adjustment. The drug is contraindicated in individuals under 16 years of age. For patients with moderate hepatic impairment (Child-Pugh score 7–9), the dose must not exceed 30 mg once daily. If a dose is missed, patients should take the next scheduled dose at the usual time and not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etom (Etoricoxib)

The evidence supporting the regulatory review of Etom is primarily drawn from formal clinical studies, including randomized controlled trials (RCTs), long-term observational studies, and systematic reviews. The research focuses on how symptoms related to inflammation and discomfort change over defined periods.

Evidence for Symptom Management in Osteoarthritis (OA)

Research exploring the use of Etom for symptoms associated with Osteoarthritis involves numerous well-designed RCTs. These studies typically compare Etom against both a placebo (an inactive substance) and other established treatments. The research explored patterns of measured outcomes when Etom was used in studies alongside other active comparators and placebo.

Studies focused on objective and subjective measurements of outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe the patterns of change measured in patient-reported scores over the short term, typically ranging from 6 to 14 weeks.

Evidence in Other Chronic Inflammatory Conditions

Evidence exploring how symptoms change in research associated with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) relies heavily on RCTs. These studies focus on conditions characterized by fluctuating or episodic manifestations and were designed to monitor outcomes reflecting systemic or functional imbalance. Research contributes to the broader evidence landscape by describing the evolution of symptoms measured in the observed populations during the study period.

Research for Use in Acute Pain and Inflammation

The evidence base for Etom in acute settings is characterized by very short-term, placebo-controlled RCTs. The primary outcomes studied included patient-reported measures of pain intensity and the time-course of observed changes after administration. Studies monitored responses over defined time intervals, with typical follow-up durations limited to a few days.

Gaps in Evidence and Areas of Uncertainty

While the evidence base is established for symptom management, a key limitation noted is that many core findings apply only to the short-term follow-up durations, meaning that long-term outcomes related to sustained functional change are not fully established. Studies highlight the need for continued monitoring of certain systemic outcomes in research contexts when Etom is studied long-term.

Key Studies & References

  1. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

Frequently Asked Questions (FAQ)

Common questions about Etom (FAQ)


Q: How long does a dose of Etom typically stay active in the body?

A: According to official regulatory pharmacokinetic data, the active substance etoricoxib has an elimination half-life of approximately 20 to 22 hours. This characteristic is described in the official product information which outlines a once-daily dosing schedule.


Q: What if I forget to use Etom one day?

A: If a dose is missed, official dosing instructions indicate that the next scheduled dose is taken at the usual time. Regulatory instructions state that a double dose should not be taken to make up for the missed one.


Q: Can I stop using Etom suddenly, or do I need to reduce the amount slowly?

A: For chronic conditions, official documents indicate that the patient's need for continued therapy should be re-evaluated periodically. Some regulatory information mentions that dose tapering may be considered in these cases.


Q: Is it possible for Etom to lose its effectiveness over time?

A: Studies and official information indicate that for long-term use, a patient's response to the medicine should be re-evaluated periodically. Official documents indicate that a lack of sustained benefit may lead to the consideration of other therapeutic options.


Q: Is Etom addictive or habit-forming?

A: Official regulatory product information does not classify Etom as a controlled substance. Furthermore, there are no warnings documented in the product information related to the medication being addictive or habit-forming.


Q: How quickly does Etom start to work after the first use?

A: According to official pharmacokinetic data, the onset of the medicine’s effect is described as being quick. The maximum concentration is reached typically about one hour after the tablet is taken.


Q: Can Etom cause problems with sleep?

A: Official regulatory documents list sleepiness, known as somnolence, as a possible side effect of Etom. Official guidance advises that any potential side effects experienced be discussed with a healthcare professional.


Q: Does Etom commonly cause weight changes?

A: Official labeling documents fluid retention, known as oedema, as a possible effect of the medication. Fluid retention is noted as a possible effect that may be associated with changes in body volume.


Q: Is it normal to feel a bit tired when taking Etom?

A: Sleepiness (somnolence) is a potential side effect that has been reported in patients using Etom. This effect is noted in the official regulatory documents.


Q: Does alcohol change how Etom works in the body?

A: Official regulatory documents describing drug interactions for Etom do not specify that alcohol consumption changes how the medicine works in the body.


Q: Is there a food or drink that needs to be avoided while using Etom?

A: Regulatory information for Etom does not list any specific foods or drinks that must be avoided. The medicine can typically be administered with or without food.


Q: Is Etom a long-term treatment or is it usually for a short time?

A: Etom is approved for a variety of conditions, including chronic inflammatory conditions like osteoarthritis, which may require long-term use. It is also approved for short-term treatment of acute pain conditions, such as post-operative dental pain.


Q: Does Etom affect concentration or the ability to drive?

A: Possible side effects like dizziness, vertigo (a spinning sensation), and sleepiness have been reported. The official labeling states that the ability to drive or operate machinery may be affected if these side effects occur.


Q: Does Etom have a 'Black Box Warning' from the FDA?

A: Regulatory documents describe the risks of serious cardiovascular events, including myocardial infarction and stroke. The risk for these serious effects is noted to increase with both the dose used and the duration of exposure.


Q: Is it true that Etom is only used for severe cases?

A: Etom is approved for managing symptoms related to chronic inflammatory conditions and for the short-term relief of pain following procedures like dental surgery. The indications range from chronic symptom management to moderate pain relief.


Q: Are there different strengths or forms of Etom available?

A: Etom is typically supplied as a film-coated tablet for oral administration. Official regulatory documents show it is available in various approved strengths, which may include 30 mg, 60 mg, 90 mg, and 120 mg.


Q: What happens if I take too much Etom, generally speaking?

A: In the event of using doses higher than officially recommended, there is a risk of serious adverse effects. Regulatory documents warn of potential harms to the gastrointestinal system and kidneys, as well as cardiovascular events.


Q: Where can I find the official regulatory information about Etom?

A: Official regulatory information is publicly available from drug agencies around the world. These documents include the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA) and Patient Information Leaflets (PIL) from national drug authorities.


Q: What are the official recommendations about getting laboratory tests while on Etom?

A: Due to potential effects on the body, official warnings recommend regular monitoring, particularly for patients using the medication long-term. This monitoring may involve checking parameters such as blood pressure, kidney function (creatinine), and liver function (ALT/AST).

How should Etom be stored and disposed of?

Storage Requirements

The official labeling for Etom (Etoricoxib) film-coated tablets mandates specific conditions to ensure product stability:

Item Requirement
Storage Temperature Store at a temperature not above 30 C.
Packaging Rules Must be kept in the original package to protect the tablets from moisture.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Etom, regulatory guidelines prohibit specific methods to protect the environment:

  • Do not throw away any medicines via wastewater or household trash.
  • Disposal of unused product must be completed according to local regulations for pharmaceutical waste, typically through a pharmacy or designated collection site.

This structure defines how the product must be stored and disposed of: the temperature and container rules preserve product quality, and the disposal rules ensure safe, environmentally appropriate handling of unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Etom found in:

A-Z Index: